ClinicalThought
View More
Here’s my take on how to optimize the switching of antiretroviral therapy in patients with virologic suppression and a history of antiretroviral resistance.
Here’s why I think using newer novel agents earlier could affect virologic suppression and mortality for people with multidrug-resistant HIV.
Lenacapavir is from a new drug class and may be a promising component of antiretroviral therapy if adherence can be ensured.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.